Page last updated: 2024-10-30

metformin and Diarrhea

metformin has been researched along with Diarrhea in 38 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.

Research Excerpts

ExcerptRelevanceReference
"BACKGROUND Metformin-associated lactic acidosis (MALA) is a relatively rare adverse effect of metformin therapy."8.12Transient Complete Blindness Due to Metformin-Associated Lactic Acidosis (MALA) Reversed with Hemodialysis. ( Barusya, C; Charokopos, A; Dumic, I; Knopps, L; Rueda Prada, L; Subramanian, A; Zurob, AS, 2022)
"Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications."6.41[Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000)
"Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world."5.51Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. ( Aguilar-Medina, EM; Centurión, D; de Jesús Acosta-Cota, S; Montes-Avila, J; Osuna-Martínez, U; Plazas-Guerrero, CG; Ramos-Payán, R; Rendón Maldonado, JG; Romero-Quintana, JG; Sánchez-López, A; Sarmiento-Sánchez, JI; Vergara-Jiménez, MJ, 2019)
"Metformin, first line medication in the treatment of type2 diabetes by millions of patients worldwide, causes gastrointestinal adverse effects (i."5.46"Metformin-resistant" folic acid producing probiotics or folic acid against metformin's adverse effects like diarrhea. ( Olgun, A, 2017)
"Patients with type 2 diabetes who are taking metformin and experience diarrhea deserve a drug-free interval before undergoing expensive and uncomfortable diagnostic tests, even when the dosage has been stable over a long period."5.31Metformin as a cause of late-onset chronic diarrhea. ( Clement, KD; Foss, MT, 2001)
"Compared with glimepiride, Sita/Met as an initial treatment led to significantly greater improvements in glycemic control and body weight changes, with a lower incidence of hypoglycemia, over 30 weeks."5.24Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. ( Chung, SC; Kim, IJ; Kim, SS; Kim, YI; Lee, KJ; Lee, SJ; Lee, YS; Park, JH, 2017)
"Compared with metformin, vildagliptin combined with metformin could significantly reduce FPG, HbA1c and body weight."5.22Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis. ( Cao, L; Ding, Y; Dong, F; Li, Y; Lin, M; Lin, S; Liu, Y; Qu, Y, 2022)
"The risk of gastrointestinal adverse events such as abdominal pain, nausea and diarrhea is higher in type 2 diabetes patients treated with metformin compared to other antidiabetic drugs."5.22Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. ( Gumprecht, J; Hendel, M; Irlik, K; Januszkiewicz, K; Kwiendacz, H; Lip, GYH; Nabrdalik, K; Skonieczna-Żydecka, K; Łoniewski, I, 2022)
"Liraglutide provided better glycaemic control and greater body weight reduction than sitagliptin when administered as add-on to metformin."5.22Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. ( Bian, F; Bosch-Traberg, H; Geng, J; Li, Y; Liu, J; Liu, Y; Luo, Y; Lv, X; Mu, Y; Peng, Y; Sun, Y; Yang, J; Zang, L, 2016)
" We performed a systematic analysis and compared the proportion of patients reporting nausea, vomiting or diarrhoea, for different doses and glucose-lowering background medications, and relative to a reference compound within the subclasses of short- (exenatide b."4.95Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. ( Abd El Aziz, MS; Bettge, K; Kahle, M; Meier, JJ; Nauck, MA, 2017)
"Digestive disorders (diarrhoea, vomiting) represent the most common metformin side-effects (around 30%) with this first-line drug treatment for type 2 diabetes."4.87Metformin and digestive disorders. ( Bouchoucha, M; Cohen, R; Uzzan, B, 2011)
"BACKGROUND Metformin-associated lactic acidosis (MALA) is a relatively rare adverse effect of metformin therapy."4.12Transient Complete Blindness Due to Metformin-Associated Lactic Acidosis (MALA) Reversed with Hemodialysis. ( Barusya, C; Charokopos, A; Dumic, I; Knopps, L; Rueda Prada, L; Subramanian, A; Zurob, AS, 2022)
"Nondiabetic patients with LAHNSCC were enrolled in the current study to receive escalating doses of metformin and CRT based on the modified toxicity probability interval design."2.94Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. ( Desai, J; Desai, PB; Gulati, S; Gutkind, JS; Jandarov, R; Mierzwa, M; Molinolo, A; Morris, JC; Palackdharry, SM; Riaz, MK; Sadraei, NH; Takiar, V; Wise-Draper, TM; Zhu, Z, 2020)
" The mean terminal half-life (t1/2 ) was 2-3 h."2.82Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes. ( Abribat, T; Allas, S; Delale, T; Julien, M; Ngo, N; Ritter, J; Sahakian, P; van der Lely, AJ, 2016)
"Metformin XR was well tolerated; gastrointestinal side effects were more common with metformin XR vs."2.71Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-c ( Brazg, RL; Bruce, S; Fujioka, K; Joyal, S; Pans, M; Raz, I; Swanink, R, 2005)
" The overall results demonstrated that the use of oral antidiabetic agents (analysed separately and together) was not associated with any significantly increased risk of any serious adverse events including hypoglycaemia and gastrointestinal disorders."2.50The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. ( Kawalec, P; Mikrut, A; Łopuch, S, 2014)
"Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications."2.41[Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000)
"Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure with reduced ejection fraction."1.62Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects. ( Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Oberoi, RK; Spring, M; Trivedi, A; Zhang, H, 2021)
"Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world."1.51Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. ( Aguilar-Medina, EM; Centurión, D; de Jesús Acosta-Cota, S; Montes-Avila, J; Osuna-Martínez, U; Plazas-Guerrero, CG; Ramos-Payán, R; Rendón Maldonado, JG; Romero-Quintana, JG; Sánchez-López, A; Sarmiento-Sánchez, JI; Vergara-Jiménez, MJ, 2019)
"Non-alcoholic fatty liver disease (NAFLD) may be associated with changes in bile acid (BA) metabolism."1.51Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. ( Appleby, RN; Khan, S; Manousou, P; Moghul, I; Neal, TD; Walters, JRF; Yee, M, 2019)
"Metformin, first line medication in the treatment of type2 diabetes by millions of patients worldwide, causes gastrointestinal adverse effects (i."1.46"Metformin-resistant" folic acid producing probiotics or folic acid against metformin's adverse effects like diarrhea. ( Olgun, A, 2017)
"Data on risk factors for Clostridium difficile infection (CDI) in diabetic patients are scarce."1.42Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study. ( Barsheshet, A; Bishara, J; Eliakim-Raz, N; Fishman, G; Goldberg, E; Stein, GY; Yahav, D; Zvi, HB, 2015)
"Metformin is a drug to improve glycemic control by reducing insulin resistance and is currently considered to be one of the first-choice drugs for type 2 diabetes mellitus (T2DM)."1.38The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. ( Hori, A; Horikawa, Y; Itoh, Y; Kitaichi, K; Okayasu, S; Suwa, T; Takeda, J; Yamamoto, M, 2012)
"We report two cases who had symptomatic vitamin B12 deficiency related to metformin use; the mechanisms are discussed."1.33Metformin-related vitamin B12 deficiency. ( Dai, LK; Jean, W; Liu, KW, 2006)
"Patients with type 2 diabetes who are taking metformin and experience diarrhea deserve a drug-free interval before undergoing expensive and uncomfortable diagnostic tests, even when the dosage has been stable over a long period."1.31Metformin as a cause of late-onset chronic diarrhea. ( Clement, KD; Foss, MT, 2001)
"Chronic diarrhea was diagnosed in 32 patients (overall prevalence of 3."1.30The prevalence of chronic diarrhea among diabetic patients. ( Goldin, E; Israeli, E; Lysy, J, 1999)

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-19902 (5.26)18.7374
1990's1 (2.63)18.2507
2000's7 (18.42)29.6817
2010's17 (44.74)24.3611
2020's11 (28.95)2.80

Authors

AuthorsStudies
Mehrpour, O1
Saeedi, F1
Hoyte, C1
Hadianfar, A1
Nakhaee, S1
Brent, J1
Rueda Prada, L1
Knopps, L1
Dumic, I1
Barusya, C1
Subramanian, A1
Charokopos, A1
Zurob, AS1
Ding, Y1
Liu, Y2
Qu, Y1
Lin, M1
Dong, F1
Li, Y2
Cao, L1
Lin, S1
Nabrdalik, K2
Skonieczna-Żydecka, K2
Irlik, K1
Hendel, M1
Kwiendacz, H2
Łoniewski, I2
Januszkiewicz, K1
Gumprecht, J2
Lip, GYH1
Mizoguchi, M1
Takemori, H2
Furukawa, S1
Ito, M2
Asai, M1
Morino, H2
Miura, T2
Yabe, D1
Shibata, T2
Drożdż, K1
Kaczmarczyk, M1
Wijata, AM1
Nalepa, J1
Holleman, F2
Nieuwdorp, M1
de Jesús Acosta-Cota, S1
Aguilar-Medina, EM1
Ramos-Payán, R1
Rendón Maldonado, JG1
Romero-Quintana, JG1
Montes-Avila, J1
Sarmiento-Sánchez, JI1
Plazas-Guerrero, CG1
Vergara-Jiménez, MJ1
Sánchez-López, A1
Centurión, D1
Osuna-Martínez, U1
Gulati, S1
Desai, J1
Palackdharry, SM1
Morris, JC1
Zhu, Z1
Jandarov, R1
Riaz, MK1
Takiar, V1
Mierzwa, M1
Gutkind, JS1
Molinolo, A1
Desai, PB1
Sadraei, NH1
Wise-Draper, TM1
Hamamoto, A1
Isogawa, K1
Takagi, M1
Oshida, K1
Patoulias, D1
Katsimardou, A1
Kalogirou, MS1
Zografou, I1
Toumpourleka, M1
Imprialos, K1
Stavropoulos, K1
Stergiou, I1
Papadopoulos, C1
Doumas, M1
Yeku, OO1
Medford, AJ1
Fenves, AZ1
Uljon, SN1
Trivedi, A1
Oberoi, RK1
Jafarinasabian, P1
Zhang, H1
Spring, M1
Flach, S1
Abbasi, S1
Dutta, S1
Lee, E1
Olgun, A1
Appleby, RN1
Moghul, I1
Khan, S1
Yee, M1
Manousou, P1
Neal, TD1
Walters, JRF1
Mendonça, FM1
Leitão, MJ1
Faria-Costa, G1
Pires Da Rosa, G1
Almeida, J1
Wysham, C1
Grimm, M1
Chen, S1
Kawalec, P1
Mikrut, A1
Łopuch, S1
Eliakim-Raz, N1
Fishman, G1
Yahav, D1
Goldberg, E1
Stein, GY1
Zvi, HB1
Barsheshet, A1
Bishara, J1
Nunez, DJ1
Yao, X1
Lin, J1
Walker, A1
Zuo, P1
Webster, L1
Krug-Gourley, S1
Zamek-Gliszczynski, MJ1
Gillmor, DS1
Johnson, SL1
Zang, L1
Geng, J1
Luo, Y1
Bian, F1
Lv, X1
Yang, J1
Liu, J1
Peng, Y1
Sun, Y1
Bosch-Traberg, H1
Mu, Y1
Allas, S1
Delale, T1
Ngo, N1
Julien, M1
Sahakian, P1
Ritter, J1
Abribat, T1
van der Lely, AJ1
Kim, SS1
Kim, IJ1
Lee, KJ1
Park, JH1
Kim, YI1
Lee, YS1
Chung, SC1
Lee, SJ1
Bettge, K1
Kahle, M1
Abd El Aziz, MS1
Meier, JJ1
Nauck, MA1
Soudet, S1
Lambert, M1
Lefèvre, G1
Maillard, H1
Huglo, D1
Hatron, PY1
Gould, M1
Sellin, JH1
Li, XJ1
Yu, YX1
Liu, CQ1
Zhang, W1
Zhang, HJ1
Yan, B1
Wang, LY1
Yang, SY1
Zhang, SH1
Bouchoucha, M1
Uzzan, B1
Cohen, R1
Yang, W1
Guan, Y1
Shentu, Y1
Li, Z1
Johnson-Levonas, AO1
Engel, SS1
Kaufman, KD1
Goldstein, BJ1
Alba, M1
Okayasu, S1
Kitaichi, K1
Hori, A1
Suwa, T1
Horikawa, Y1
Yamamoto, M1
Takeda, J1
Itoh, Y1
Fujioka, K1
Brazg, RL1
Raz, I1
Bruce, S1
Joyal, S1
Swanink, R1
Pans, M1
Liu, KW1
Dai, LK1
Jean, W1
Geberhiwot, T1
Jones, AF1
Lysy, J1
Israeli, E1
Goldin, E1
Raju, B1
Resta, C1
Tibaldi, JT1
Stades, AM1
Hoekstra, JB1
Foss, MT1
Clement, KD1
Lim, P1
Khoo, OT1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)[NCT02008682]Phase 4368 participants (Actual)Interventional2013-12-31Completed
A Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (Janumet®) Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus[NCT00993187]Phase 4292 participants (Actual)Interventional2010-05-04Completed
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy[NCT00813995]Phase 3395 participants (Actual)Interventional2008-12-09Completed
The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient: Randomized Clinical Trial[NCT04689971]Phase 2/Phase 360 participants (Anticipated)Interventional2020-11-03Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in 7-point Self-measured Plasma Glucose Profile

Mean change from baseline in mean of 7-point self-measured plasma glucose at week 26. The 7-point self-measured plasma glucose levels were measured before and after (120 minutes after the start of the meal) the three main meals (breakfast, lunch and dinner), and at bed time. (NCT02008682)
Timeframe: Week 0, week 26

Interventionmmol/L (Mean)
Liraglutide-2.25
Sitagliptin-1.36

Change From Baseline in Fasting Plasma Glucose

Mean change from baseline in fasting plasma glucose (FPG) at Week 26. (NCT02008682)
Timeframe: Week 0, week 26

Interventionmmol/L (Mean)
Liraglutide-2.347
Sitagliptin-1.205

Change From Baseline in Glycosylated Haemoglobin (HbA1c)

Mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26. (NCT02008682)
Timeframe: Week 0, week 26

InterventionPercent (%) glycosylated haemoglobin (Mean)
Liraglutide-1.666
Sitagliptin-0.969

Number of Confirmed Hypoglycaemic Episodes

confirmed hypoglycaemic episode defined as severe (unable to treat her/himself) or biochemically confirmed by a plasma glucose < 3.1 mmol/L (NCT02008682)
Timeframe: Weeks 0-26

Interventionepisodes (Number)
Liraglutide2
Sitagliptin1

Subjects Who Achieve (Yes/no) HbA1c Below 7.0 % (American Diabetes Association Target)

Calculated as the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 26 (NCT02008682)
Timeframe: After 26 weeks of treatment

Interventionpercentage of subjects (Number)
Liraglutide76.5
Sitagliptin52.6

Subjects Who Achieve (Yes/no) HbA1c Below or Equal to 6.5 % (American Association of Clinical Endocrinologists Target)

Calculated as the percentage of subjects achieving treatment target of HbA1c <= 6.5% at Week 26 (NCT02008682)
Timeframe: After 26 weeks of treatment

Interventionpercentage of subjects (Number)
Liraglutide61.7
Sitagliptin26.3

Change From Baseline in Body Weight at Week 30

Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline) (NCT00993187)
Timeframe: Baseline and Week 30

Interventionkg (Least Squares Mean)
Sitagliptin/Metformin-0.83
Glimepiride0.90

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30

Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline). (NCT00993187)
Timeframe: Baseline and Week 30

Interventionmg/dL (Least Squares Mean)
Sitagliptin/Metformin-47.0
Glimepiride-23.5

Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30

HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline). (NCT00993187)
Timeframe: Baseline and Week 30

InterventionPercent of total hemoglobin (Least Squares Mean)
Sitagliptin/Metformin-1.5
Glimepiride-0.7

Number of Participants Who Discontinued Study Drug Due to an Adverse Event

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 30 weeks

InterventionParticipants (Number)
Sitagliptin/Metformin8
Glimepiride8

Number of Participants Who Experienced at Least One Adverse Event (AE)

An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 32 weeks

InterventionParticipants (Number)
Sitagliptin/Metformin88
Glimepiride101

Percentage of Participants With HbA1C < 7.0% at Week 30

HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). (NCT00993187)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin/Metformin81.2
Glimepiride40.1

Percentage of Participants With One or More Episodes of Hypoglycemia

Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required. (NCT00993187)
Timeframe: Up to Week 30

InterventionPercentage of participants (Number)
Sitagliptin/Metformin5.5
Glimepiride20.1

Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24

Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00813995)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-43.4
Placebo-10.0

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00813995)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-20.3
Placebo0.5

Change From Baseline in Hemoglobin A1c (A1C) at Week 24

A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00813995)
Timeframe: Baseline and Week 24

InterventionPercent (Least Squares Mean)
Sitagliptin-1.02
Placebo-0.14

Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day

A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00813995)
Timeframe: Baseline and Week 24

InterventionPercent (Least Squares Mean)
Sitagliptin-0.84
Placebo-0.01

Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day

A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00813995)
Timeframe: Baseline and Week 24

InterventionPercent (Least Squares Mean)
Sitagliptin-1.14
Placebo-0.21

Reviews

9 reviews available for metformin and Diarrhea

ArticleYear
Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis.
    European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:8

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Dizziness; Drug Therapy, Combinatio

2022
Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Abdominal Pain; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Humans; Hypoglycem

2022
Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Diabetes & metabolism, 2020, Volume: 46, Issue:4

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Glucagon-Like Peptide

2020
Once weekly exenatide: efficacy, tolerability and place in therapy.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:10

    Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Drug Administration

2013
The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes/metabolism research and reviews, 2014, Volume: 30, Issue:4

    Topics: Administration, Oral; Diabetes Mellitus, Type 2; Diarrhea; Dipeptidyl-Peptidase IV Inhibitors; Drug

2014
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:3

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Exenatide;

2017
Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.
    Clinical endocrinology, 2011, Volume: 74, Issue:3

    Topics: Dehydroepiandrosterone Sulfate; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin; Nausea; Pi

2011
Metformin and digestive disorders.
    Diabetes & metabolism, 2011, Volume: 37, Issue:2

    Topics: Bile Acids and Salts; Diabetes Mellitus, Type 2; Diarrhea; Digestive System Diseases; Glucose; Human

2011
[Metformin efficacious in poorly controlled diabetes mellitus type 2].
    Nederlands tijdschrift voor geneeskunde, 2000, Sep-30, Volume: 144, Issue:40

    Topics: Abdominal Pain; Acidosis, Lactic; Aged; Blood Glucose; Contraindications; Diabetes Mellitus; Diabete

2000

Trials

8 trials available for metformin and Diarrhea

ArticleYear
Clinical Trial: Probiotics in Metformin Intolerant Patients with Type 2 Diabetes (ProGasMet).
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 168

    Topics: Abdominal Pain; Diabetes Mellitus, Type 2; Diarrhea; Double-Blind Method; Humans; Metformin; Polyest

2023
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
    Cancer, 2020, 01-15, Volume: 126, Issue:2

    Topics: Acute Kidney Injury; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy

2020
Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:7

    Topics: Adult; Apolipoproteins B; Area Under Curve; Bile Acids and Salts; Blood Glucose; Cholesterol, LDL; C

2016
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Asian People; Blood Glucose; Body Weight; Chin

2016
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:9

    Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Bli

2016
Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
    Journal of diabetes, 2017, Volume: 9, Issue:4

    Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Blind Method; Drug Th

2017
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Journal of diabetes, 2012, Volume: 4, Issue:3

    Topics: Abdominal Pain; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Diarrhea

2012
Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-c
    Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:1

    Topics: Adult; Aged; Blood Glucose; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus, Type 2

2005

Other Studies

21 other studies available for metformin and Diarrhea

ArticleYear
Distinguishing characteristics of exposure to biguanide and sulfonylurea anti-diabetic medications in the United States.
    The American journal of emergency medicine, 2022, Volume: 56

    Topics: Abdominal Pain; Acidosis; Adolescent; Adult; Aged; Child; Creatinine; Diabetes Mellitus; Diarrhea; D

2022
Transient Complete Blindness Due to Metformin-Associated Lactic Acidosis (MALA) Reversed with Hemodialysis.
    The American journal of case reports, 2022, Apr-18, Volume: 23

    Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Blindness; Diabetes Mellitus, Type 2; Diarrhea; Female;

2022
Increased expression of glucagon-like peptide-1 and cystic fibrosis transmembrane conductance regulator in the ileum and colon in mouse treated with metformin.
    Endocrine journal, 2023, Feb-28, Volume: 70, Issue:2

    Topics: Animals; Caco-2 Cells; Colon; Creosote; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regula

2023
Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease.
    European journal of pharmacology, 2019, Nov-15, Volume: 863

    Topics: Animals; Chalcones; Collagen; Cytokines; Diarrhea; Drug Interactions; Eating; Liver; Male; Metformin

2019
Mouse model of metformin-induced diarrhea.
    BMJ open diabetes research & care, 2020, Volume: 8, Issue:1

    Topics: Animals; Diabetes Mellitus, Type 2; Diarrhea; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, In

2020
Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure.
    The New England journal of medicine, 2021, May-20, Volume: 384, Issue:20

    Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Coronary Artery Disease; Creatinine; Diabetes Mellitus,

2021
Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects.
    Clinical drug investigation, 2021, Volume: 41, Issue:7

    Topics: Administration, Oral; Adult; Area Under Curve; Diarrhea; Drug Interactions; Female; Half-Life; Healt

2021
"Metformin-resistant" folic acid producing probiotics or folic acid against metformin's adverse effects like diarrhea.
    Medical hypotheses, 2017, Volume: 106

    Topics: Animals; Diabetes Mellitus, Type 2; Diarrhea; Directed Molecular Evolution; Folic Acid; Gastrointest

2017
Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
    PloS one, 2019, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Bile Acids and Salts; Cholestenones; Diarrhea;

2019
Chronic diarrhea: an unusual clinical presentation of vitamin B
    Internal and emergency medicine, 2019, Volume: 14, Issue:3

    Topics: Diabetes Mellitus, Type 1; Diarrhea; Humans; Male; Metformin; Middle Aged; Vitamin B 12; Vitamin B 1

2019
Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Clostridioides difficile; Clostridium Infectio

2015
Long term use of metformin in idiopathic cyclic edema, report of thirteen cases and review of the literature.
    Pharmacological research, 2017, Volume: 119

    Topics: Adult; Aged; Capillary Permeability; Diarrhea; Edema; Female; Humans; Hypoglycemic Agents; Male; Met

2017
Diabetic diarrhea.
    Current gastroenterology reports, 2009, Volume: 11, Issue:5

    Topics: Algorithms; Antidiarrheals; Celiac Disease; Clonidine; Colitis; Diabetes Complications; Diabetes Mel

2009
The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus.
    Biological & pharmaceutical bulletin, 2012, Volume: 35, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Asian People

2012
Metformin-related vitamin B12 deficiency.
    Age and ageing, 2006, Volume: 35, Issue:2

    Topics: Aged, 80 and over; Diabetes Mellitus, Type 2; Diarrhea; Female; Humans; Hypoglycemic Agents; Metform

2006
Treatment of infertility in the polycystic ovary syndrome.
    The New England journal of medicine, 2007, May-10, Volume: 356, Issue:19

    Topics: Clomiphene; Diarrhea; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglyce

2007
Diabetes and bowel habits.
    The New England journal of medicine, 1983, May-19, Volume: 308, Issue:20

    Topics: Anal Canal; Diabetes Complications; Diabetes Mellitus; Diarrhea; Fecal Incontinence; Humans; Metform

1983
The prevalence of chronic diarrhea among diabetic patients.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Autonomic Nervous System Dis

1999
Metformin and late gastrointestinal complications.
    The American journal of medicine, 2000, Aug-15, Volume: 109, Issue:3

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diarrhea; Drug Administration Schedule; Female; Humans; Hypo

2000
Metformin as a cause of late-onset chronic diarrhea.
    Pharmacotherapy, 2001, Volume: 21, Issue:11

    Topics: Chronic Disease; Diabetes Mellitus, Type 2; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin

2001
Metformin compared with tolbutamide in the treatment of maturity-onset diabetes mellitus.
    The Medical journal of Australia, 1970, Feb-07, Volume: 1, Issue:6

    Topics: Adult; Diabetes Mellitus; Diarrhea; Female; Humans; Hyperglycemia; Male; Metformin; Middle Aged; Tol

1970